Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3′-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor-Reference-Cited by-同舟云学术

Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3′-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor

Published:2017-06-05 Issue:12 Volume:60 Page:4932-4948
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ye Xiang-Yang¹²^ORCID,Chen Stephanie Y.¹²,Wu Shung¹²,Yoon David S.¹²,Wang Haixia¹²,Hong Zhenqiu¹²,O’Connor Stephen P.¹²,Li Jun¹²,Li James J.¹²,Kennedy Lawrence J.¹²,Walker Steven J.¹²,Nayeem Akbar¹²,Sheriff Steven¹²,Camac Daniel M.¹²,Ramamurthy Vidyhashankar¹²,Morin Paul E.¹²,Zebo Rachel¹²,Taylor Joseph R.¹²,Morgan Nathan N.¹²,Ponticiello Randolph P.¹²,Harrity Thomas¹²,Apedo Atsu¹²,Golla Rajasree¹²,Seethala Ramakrishna¹²,Wang Mengmeng¹²,Harper Timothy W.¹²,Sleczka Bogdan G.¹²,He Bin¹²,Kirby Mark¹²,Leahy David K.¹²,Li Jianqing¹²,Hanson Ronald L.¹²,Guo Zhiwei¹²,Li Yi-Xin¹²,DiMarco John D.¹²,Scaringe Raymond¹²,Maxwell Brad¹²^ORCID,Moulin Frederick¹²,Barrish Joel C.¹²,Gordon David A.¹²,Robl Jeffrey A.¹²

Affiliation:

1. Discovery Chemistry, ‡Pharmaceutical Candidate Optimization, §Computer-Assisted Drug Design, ∥Metabolic Diseases Biology, ⊥Lead Evaluation, #Process Chemistry, ∇Chemical Synthesis, ○Discovery Toxicology, Research and Development, Bristol-Myers Squibb, 350 Carter Road, Princeton, New Jersey 08540, United States

2. Molecular Structure and Design, ¶Protein Science, +Solid State Chemistry, Research and Development, Bristol-Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00211

Reference52 articles.

1. Burden of Diabetes on the Ability to Work

2. Global Report on Diabetes;World Health Organization (WHO):Geneva, 2016; http://www.who.int/diabetes/global-report/en/(accessed April 2, 2017).

3. Obesity and cortisol

4. Inhibition of 11ß-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target

5. Mechanisms of Disease: selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel 2-(Adamantan-1-ylamino)Thiazol-4(5H)-One Derivatives and Their Inhibitory Activity towards 11β-HSD1—Synthesis, Molecular Docking and In Vitro Studies;International Journal of Molecular Sciences;2021-08-10

2. The ratio of ursodeoxycholyltaurine to 7‐oxolithocholyltaurine serves as a biomarker of decreased 11β‐hydroxysteroid dehydrogenase 1 activity in mouse;British Journal of Pharmacology;2021-02-04

3. Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 as Potential Drugs for Type 2 Diabetes Mellitus—A Systematic Review of Clinical and In Vivo Preclinical Studies;Scientia Pharmaceutica;2021-01-05

4. Metabolic Profiling of a CB2 Agonist, AM9338, Using LC-MS and Microcoil-NMR: Identification of a Novel Dihydroxy Adamantyl Metabolite;Frontiers in Pharmacology;2020-09-30

5. Application of carbamyl in structural optimization;Bioorganic Chemistry;2020-05